Coldstream Capital Management Inc Summit Therapeutics Inc. Transaction History
Coldstream Capital Management Inc
- $4.64 Billion
- Q1 2025
A detailed history of Coldstream Capital Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 128 shares of SMMT stock, worth $3,249. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128Holding current value
$3,249% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86MCall Options Held
1.55MPut Options Held
3.14M-
Baker Bros. Advisors LP New York, NY24.4MShares$620 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$296 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$201 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$167 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$123 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.11B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...